<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/9F250460-FEB3-4FCF-B06C-1340468D1058"><gtr:id>9F250460-FEB3-4FCF-B06C-1340468D1058</gtr:id><gtr:name>Viva Bioscience Limited</gtr:name><gtr:address><gtr:line1>1 COLLETON CRESCENT</gtr:line1><gtr:city>EXETER</gtr:city><gtr:postCode>EX2 4DG</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9F250460-FEB3-4FCF-B06C-1340468D1058" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>9F250460-FEB3-4FCF-B06C-1340468D1058</gtr:id><gtr:name>Viva Bioscience Limited</gtr:name><gtr:address><gtr:line1>1 COLLETON CRESCENT</gtr:line1><gtr:city>EXETER</gtr:city><gtr:postCode>EX2 4DG</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>15000.0</gtr:offerGrant><gtr:projectCost>25000.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E55330E3-17BD-4673-9EED-928799DE71A4"><gtr:id>E55330E3-17BD-4673-9EED-928799DE71A4</gtr:id><gtr:firstName>Ben</gtr:firstName><gtr:surname>Voysey</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=700315"><gtr:id>88900054-290A-407D-89E2-48F0459D217E</gtr:id><gtr:title>VIVAbind? - an innovative matrix for protein purification</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Proof of Market</gtr:grantCategory><gtr:grantReference>700315</gtr:grantReference><gtr:abstractText>Enzymes and antibodies (biologicals) are used in a wide range of applications including biomedical research, diagnostic blood tests, as medicines, in industrial production, and in everyday goods such as washing powders and food additives.
New and improved approaches to production of biologicals that overcome limitations with existing purification technology will bring considerable commercial advantage and be of great benefit to researchers and manufacturers alike.
VIVA Bioscience wishes to develop novel materials for the enhanced purification of biologicals by improving on existing technology, a process which is expected to generate additional Intellectual Property, both for generic application and for the specific isolation of targets of key importance to cellular protein degradation research and therapeutic drug development in which VIVA is intimately involved.

Cellular protein degradation is essentially the waste disposal, recycling, and sustainability mechanism of living cells. Proteins involved in this process are critical to the functioning of virtually every cell type in both health and disease and are thus of very considerable therapeutic potential. This Proof of Market study is necessary to demonstrate clearly that there is a valuable market for innovative and improved products and that they may be developed cost-effectively. The new technology and applications to be explored are based on a patent-protected approach allowing the production of novel materials for use in protein purification which offers considerable scientific and commercial advantage over those currently available. In particular, a low cost, simple manufacturing process resulting in adaptable, non-hazardous, environmentally friendly materials with high purification capacity.</gtr:abstractText><gtr:fund><gtr:end>2014-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2013-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>15000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">700315</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>